The global Liquid Biopsy Market size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The market is experiencing significant growth due to the rising prevalence of cancer worldwide, rapid advancements in cancer diagnostics, and the increasing preference for minimally invasive testing methods. As healthcare providers and patients seek more accurate, faster, and less invasive diagnostic solutions, liquid biopsy has emerged as a transformative technology in precision oncology.

Liquid biopsy enables the detection of tumor-related genetic alterations through blood samples, eliminating the need for invasive tissue biopsies in many cases. The technology has become increasingly important in cancer screening, treatment selection, therapy monitoring, and recurrence detection. Furthermore, ongoing research initiatives focused on developing advanced liquid biopsy assays and multi-cancer early detection (MCED) tests are creating substantial opportunities for future market expansion.

Growing Demand for Minimally Invasive Cancer Diagnostics Driving Market Growth

One of the primary factors driving the liquid biopsy market is the growing demand for minimally invasive diagnostic procedures. Traditional tissue biopsies often involve surgical intervention, patient discomfort, procedural risks, and limitations in repeat testing. In contrast, liquid biopsy requires only a simple blood sample, making it safer, faster, and more convenient for both patients and healthcare providers.

The increasing global cancer burden is further accelerating demand for advanced diagnostic technologies. Healthcare systems are focusing on early detection and personalized treatment strategies to improve patient outcomes. Liquid biopsy provides real-time insights into tumor biology, enabling clinicians to monitor disease progression and treatment effectiveness more efficiently than conventional diagnostic approaches.

Download a free sample copy of the Liquid Biopsy Market report to understand detailed coverage and inclusions in the final report

Additionally, the ability of liquid biopsy to identify genetic mutations and resistance mechanisms supports precision medicine approaches, allowing oncologists to tailor therapies based on individual patient profiles.

Technological Advancements Enhancing Market Adoption

Rapid innovation in genomic technologies is significantly strengthening the capabilities of liquid biopsy platforms. Advances in sequencing technologies, bioinformatics, and biomarker discovery are improving test sensitivity, specificity, and clinical utility.

The development of multi-cancer early detection tests is emerging as one of the most promising trends in the market. These advanced screening solutions aim to identify multiple cancer types from a single blood sample, enabling earlier intervention and potentially improving survival rates.

Regulatory approvals continue to strengthen industry confidence and accelerate commercialization. For example, recent approvals of liquid biopsy-based companion diagnostics have demonstrated the growing acceptance of these technologies within mainstream clinical practice.

The expanding role of liquid biopsy in monitoring treatment response, identifying minimal residual disease (MRD), and detecting cancer recurrence is also broadening its application across the oncology care continuum.

Emerging Trends Reshaping the Liquid Biopsy Industry

Expansion of Multi-Cancer Early Detection (MCED) Testing

Healthcare providers and biotechnology companies are increasingly investing in blood-based cancer screening technologies capable of detecting multiple cancers at early stages. This trend is expected to transform preventive oncology and population-level cancer screening programs.

Advancements in Next-Generation Sequencing (NGS)

NGS-based liquid biopsy platforms are becoming more accessible due to declining sequencing costs and improved analytical accuracy. These platforms enable comprehensive genomic profiling and support personalized treatment decisions.

Growing Integration with Precision Medicine

Liquid biopsy is increasingly being incorporated into precision oncology programs to support targeted therapies, monitor treatment effectiveness, and identify resistance mutations in real time.

Artificial Intelligence and Bioinformatics Integration

The use of AI-powered analytics and advanced bioinformatics tools is improving biomarker interpretation, data processing efficiency, and clinical decision-making, further enhancing the value of liquid biopsy technologies.

Key Market Trends & Insights

• North America dominated the liquid biopsy market with the largest revenue share of 50.99% in 2025, driven by high cancer prevalence, technological innovation, favorable reimbursement frameworks, and strong industry participation.
• The U.S. accounted for the largest market share in North America in 2025, supported by increasing FDA approvals, substantial investments in biotechnology research, and growing adoption of advanced cancer diagnostics.
• The multi-gene-parallel analysis (NGS) segment held the largest revenue share of 76.67% in 2025 and is expected to grow at the fastest rate during the forecast period due to its ability to identify multiple tumor-related mutations with high accuracy.
• The circulating nucleic acids segment accounted for the largest revenue share of 35.38% in 2025, supported by the growing use of circulating tumor DNA (ctDNA) as a highly effective cancer biomarker.
• The cancer application segment dominated the market with a revenue share of 86.47% in 2025, reflecting the increasing use of liquid biopsy technologies in cancer detection, monitoring, and treatment planning.
• Growing investments in early cancer detection programs and precision medicine initiatives continue to create significant growth opportunities for industry participants.

Looking for more specific insights? Customize this report to suite your business needs

Market Size & Forecast

• 2025 Market Size: USD 13.60 Billion
• 2033 Projected Market Size: USD 32.57 Billion
• CAGR (2026-2033): 11.52%
• North America: Largest market in 2025
• Asia Pacific: Fastest growing market

Key Liquid Biopsy Company Insights

The liquid biopsy market is highly competitive and characterized by continuous innovation, strategic partnerships, acquisitions, and product launches. Leading companies are investing heavily in research and development to improve test accuracy, expand clinical applications, and strengthen their market positions.

Guardant Health

Guardant Health is a leading precision oncology company specializing in liquid biopsy technologies for cancer detection, treatment selection, and disease monitoring. The company has developed advanced blood-based assays that support precision medicine initiatives and personalized cancer care. Its strong portfolio of companion diagnostics and genomic profiling solutions continues to strengthen its global market presence.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific is a major provider of life sciences technologies, molecular diagnostics solutions, and genomic analysis platforms. The company supports liquid biopsy applications through advanced sequencing systems, biomarker analysis tools, and laboratory solutions that enable comprehensive cancer diagnostics and research.

ANGLE plc

ANGLE plc focuses on liquid biopsy technologies designed for cancer diagnosis and disease monitoring. The company specializes in circulating tumor cell (CTC) analysis and continues to expand its clinical applications through ongoing innovation and strategic collaborations.

Key Liquid Biopsy Companies

The following companies have been profiled for this study on the liquid biopsy market:

• ANGLE plc
• Oncimmune Holdings PLC
• Guardant Health
• Myriad Genetics, Inc.
• Biocept, Inc.
• Lucence Health Inc.
• Freenome Holdings, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Epigenomics AG

Conclusion

The global liquid biopsy market is entering a phase of accelerated growth as healthcare systems increasingly prioritize early cancer detection, precision medicine, and minimally invasive diagnostics. Continuous advancements in next-generation sequencing, biomarker discovery, and multi-cancer early detection technologies are expanding the clinical utility of liquid biopsy across the oncology landscape. With strong support from regulatory agencies, growing investments in cancer research, and increasing adoption of personalized treatment strategies, liquid biopsy is expected to play a central role in the future of cancer diagnostics and patient care. As innovation continues to reshape the industry, market participants that focus on technological advancement, strategic collaborations, and clinical validation will be best positioned to capitalize on emerging opportunities.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…